title: Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
abstract: To evaluate antibody response induced by trivalent inactivated influenza vaccine (TIV) against circulating influenza A (H3N2) strains in healthy adults during the 2010/11 and 2011/12 seasons, a hemagglutination-inhibition (HI) assay was utilized to calculate geometric mean antibody titer (GMT), seroprotection rate (post vaccination HI titers of ≥1 :40), and seroresponse rate (4-fold increase in antibody level). In the 2010/11 season, GMT increased 1.8- to 2.0-fold following the first dose of TIV against 3 circulating strains and 2.2-fold following the second compared to before vaccination. The seroresponse rate ranged from 22% to 26% following the first dose of TIV and from 31% to 33% following the second (n = 54 ). The seroprotection rate increased from a range of 6% to 13% to a range of 26% to 33% following the first dose of TIV and to a range of 37% to 42% following the second (n = 54 ). In the 2011/12 season, GMT increased 1.4-fold against A/Osaka/110/2011 and 1.8-fold against A/Osaka/5/2012. For A/Osaka/110/2011, the seroresponse rate was 29%, and the seroprotection rate increased from 26% to 55% following vaccination (n = 31 ). For A/Osaka/5/2012, the seroresponse rate was 26%, and the seroprotection rate increased from 68% to 84% following vaccination (n = 31 ). HI assays with reference antisera demonstrated that the strains in the 2011/12 season were antigenically distinct from vaccine strain (A/Victoria/210/2009). In conclusion, the vaccination increased the seroprotection rate against circulating H3N2 strains in the 2010/11 and 2011/12 seasons. Vaccination of TIV might have potential to induce reactive antibodies against antigenically distinct circulating H3N2 viruses.
authors.affiliation: a Department of Infectious Diseases ; Osaka Prefectural Institute of Public Health ; Osaka , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hiroi
authors.forename: Saeko
authors.initials: S
authors.lastname: Morikawa
authors.forename: Keiko
authors.initials: K
authors.lastname: Nakata
authors.forename: Akiko
authors.initials: A
authors.lastname: Maeda
authors.forename: Tsuneji
authors.initials: T
authors.lastname: Kanno
authors.forename: Shin
authors.initials: S
authors.lastname: Irie
authors.forename: Satoko
authors.initials: S
authors.lastname: Ohfuji
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hirota
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Kase
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D064368:Healthy Volunteers; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology*; D008297:Male; D008875:Middle Aged
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines
keywords: ACIP, Advisory Committee on Immunization Practices; EMA, European Medicines Agency; GMT, geometric mean antibody titer; H3N2; HI, hemagglutination-inhibition; TIV, trivalent inactivated influenza vaccine; antibody; circulating viruses; influenza; vaccine